Cargando…

Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis

BACKGROUND: Topical Janus kinase (JAK) inhibitors are being developed for the treatment of mild to moderate atopic dermatitis. However, comparative evidence on their safety profiles is still limited. AIM: This study aimed to compare the relative safety of topic JAK inhibitors in patients with atopic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves, Carlos, Penedones, Ana, Mendes, Diogo, Batel Marques, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366300/ https://www.ncbi.nlm.nih.gov/pubmed/37074513 http://dx.doi.org/10.1007/s11096-023-01569-x

Ejemplares similares

Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses
por: Alves, Carlos, et al.
Publicado: (2020)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
por: Batel-Marques, Francisco, et al.
Publicado: (2019)

A systematic review of observational studies evaluating costs of adverse drug reactions
por: Batel Marques, Francisco, et al.
Publicado: (2016)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Singh, Rhea, et al.
Publicado: (2020)

Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
por: Li, Chenyang, et al.
Publicado: (2022)

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Le, Michelle, et al.
Publicado: (2021)

A comparison between two recommendations to conduct and report systematic reviews on drug’s safety
por: Penedones, Ana, et al.
Publicado: (2019)

Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis
por: Lee, Kevin P., et al.
Publicado: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients
por: Mendes, Diogo, et al.
Publicado: (2020)

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
por: Tsai, Hou-Ren, et al.
Publicado: (2021)

Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis
por: Chen, Qianyu, et al.
Publicado: (2023)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
por: SEDEH, Farnam B., et al.
Publicado: (2022)

Recommendations to conduct and report systematic reviews in medical literature: a scoping review
por: Penedones, Ana, et al.
Publicado: (2019)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
por: Caudrelier, Nicolas, et al.
Publicado: (2023)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
por: Nguyen, Jannett, et al.
Publicado: (2020)

Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
por: Figueiredo, Daniel, et al.
Publicado: (2023)

Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
por: Martín-Santiago, Ana, et al.
Publicado: (2022)

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
por: Gooderham, Melinda J., et al.
Publicado: (2019)

A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(®)) in client‐owned dogs with atopic dermatitis
por: Cosgrove, Sallie B., et al.
Publicado: (2013)

Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials
por: £abędź, Natalia, et al.
Publicado: (2019)

Number needed to treat (NNT) in clinical literature: an appraisal
por: Mendes, Diogo, et al.
Publicado: (2017)

Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
por: Carr, Warner W.
Publicado: (2013)

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2018)

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
por: Segal, Audrey O, et al.
Publicado: (2013)

Topical tacrolimus as treatment of atopic dermatitis
por: Furue, Masutaka, et al.
Publicado: (2009)

Topical steroid addiction in atopic dermatitis
por: Fukaya, Mototsugu, et al.
Publicado: (2014)

Topical Therapy in Atopic Dermatitis in Children
por: Sathishkumar, Dharshini, et al.
Publicado: (2016)

Tolerability of Topical Treatments for Atopic Dermatitis
por: Draelos, Zoe D., et al.
Publicado: (2019)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
por: Soto, Elena, et al.
Publicado: (2020)

Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore
por: Yew, Yik Weng, et al.
Publicado: (2023)

Staphylococcus aureus resistance to topical antimicrobials in atopic dermatitis
por: Bessa, Giancarlo Rezende, et al.
Publicado: (2016)

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
por: Zhao, Yan, et al.
Publicado: (2021)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
por: Narla, Shanthi, et al.
Publicado: (2020)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2r1kjo7d1rr2b495oodh3vech6